首页>投融资
CG Oncology
增发
CG Oncology (formerly Cold Genesys) is a privately funded, oncolytic immunotherapy company focused on developing threapeutics for bladder cancer.The company is based in Newport Beach, CA.In August 2023, CG Oncology Inc announced the closing of an oversubscribed $105 million crossover financing round to advance clinical-stage bladder cancer pipeline.In November 2022, CG Oncology Inc announce the closing of an oversubscribed $120 million Series E financing round.In December 2020 CG Oncology announced the closing of a $47 million Series D preferred stock financing.In March 2019, the company raised $22 million through series C preferred stock financing.In August 2015, Cold Genesys raised $10 million through the completion of a series B financing round.In July 2014, Cold Genesys raised $13.57 million from a series A financing round
基本信息
-
公司全称CG Oncology Inc
-
类型溶瘤免疫疗法开发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址400 Spectrum Center Drive Suite #2040 IRVINE CALIFORNIA 92618; US; Telephone: +19492886298; Fax: +19492886298;
-
联系电话1-949-4093700
-
邮箱alex.yeung@coldgenesys.net
-
成立时间2010-01-01
投融资
-
2024-12-16增发2.38亿美元未透露
-
2024-01-25上市3.53亿美元未透露
-
2023-08-02未透露1.05亿美元Foresite CapitalRA CapitalMalinLongitude Capital德诚资本汇桥资本Acorn BioventuresJanus Henderson InvestorsBVF PartnersAvidity Partners
-
2022-11-15E~PreIPO1.2亿美元MalinRA Capital汇桥资本ORI CapitalSirona Capital德诚资本Longitude CapitalAcorn Bioventures
-
2020-12-10D轮4700万美元Perseverance CapitalCamford CapitalORI CapitalKissei Pharmaceutical
-
2019-03-18C轮2200万美元Perseverance CapitalORI Capital
-
2015-08-05B轮1000万美元Whitesun Healthcare VenturesWI Harper Group汇桥资本
- 加载更多
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息